These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 26554283)

  • 21. Aripiprazole augmentation in 13 patients with refractory obsessive-compulsive disorder: a case series.
    Higuma H; Kanehisa M; Maruyama Y; Ishitobi Y; Tanaka Y; Tsuru J; Hanada H; Kodama K; Isogawa K; Akiyoshi J
    World J Biol Psychiatry; 2012 Jan; 13(1):14-21. PubMed ID: 22256827
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacological management of treatment-resistant obsessive-compulsive disorder.
    Abudy A; Juven-Wetzler A; Zohar J
    CNS Drugs; 2011 Jul; 25(7):585-96. PubMed ID: 21699270
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Optimal treatment for obsessive compulsive disorder: a randomized controlled feasibility study of the clinical-effectiveness and cost-effectiveness of cognitive-behavioural therapy, selective serotonin reuptake inhibitors and their combination in the management of obsessive compulsive disorder.
    Fineberg NA; Baldwin DS; Drummond LM; Wyatt S; Hanson J; Gopi S; Kaur S; Reid J; Marwah V; Sachdev RA; Pampaloni I; Shahper S; Varlakova Y; Mpavaenda D; Manson C; O'Leary C; Irvine K; Monji-Patel D; Shodunke A; Dyer T; Dymond A; Barton G; Wellsted D
    Int Clin Psychopharmacol; 2018 Nov; 33(6):334-348. PubMed ID: 30113928
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Systematic Review and Meta-Analysis: Early Treatment Responses of Selective Serotonin Reuptake Inhibitors and Clomipramine in Pediatric Obsessive-Compulsive Disorder.
    Varigonda AL; Jakubovski E; Bloch MH
    J Am Acad Child Adolesc Psychiatry; 2016 Oct; 55(10):851-859.e2. PubMed ID: 27663940
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A comparative, single-blind, randomized study on quetiapine and aripiperazole augmentation in treatment of selective serotonin reuptake inhibitor refractory obsessive-compulsive disorder.
    Talaei A; Hosseini FF; Aghili Z; Akhondzadeh S; Asadpour E; Mehramiz NJ; Forouzanfar F
    Can J Physiol Pharmacol; 2020 Apr; 98(4):236-242. PubMed ID: 32228235
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Obsessive-Compulsive Disorders.
    Mathews C
    Continuum (Minneap Minn); 2021 Dec; 27(6):1764-1784. PubMed ID: 34881735
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Amisulpiride augmentation in treatment resistant obsessive-compulsive disorder: an open trial.
    Metin O; Yazici K; Tot S; Yazici AE
    Hum Psychopharmacol; 2003 Aug; 18(6):463-7. PubMed ID: 12923825
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Diversity of obsessive-compulsive disorder and pharmacotherapy associated with obsessive-compulsive spectrum disorders].
    Nakamae T
    Seishin Shinkeigaku Zasshi; 2011; 113(10):1016-25. PubMed ID: 22187889
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacotherapy for obsessive compulsive disorder in clinical practice - Data of 842 inpatients from the International AMSP Project between 1994 and 2012.
    Poppe C; Müller ST; Greil W; Walder A; Grohmann R; Stübner S
    J Affect Disord; 2016 Aug; 200():89-96. PubMed ID: 27130958
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-term outcome in adults with obsessive-compulsive disorder.
    Bloch MH; Green C; Kichuk SA; Dombrowski PA; Wasylink S; Billingslea E; Landeros-Weisenberger A; Kelmendi B; Goodman WK; Leckman JF; Coric V; Pittenger C
    Depress Anxiety; 2013 Aug; 30(8):716-22. PubMed ID: 23532944
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Evidence-based pharmacotherapy and other somatic treatment approaches for obsessive-compulsive disorder: state of the art].
    Kordon A; Zurowski B; Wahl K; Hohagen F
    Nervenarzt; 2011 Mar; 82(3):319-20, 322-4. PubMed ID: 21340636
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Risperidone augmentation of specific serotonin reuptake inhibitors in the treatment of refractory obsessive-compulsive disorder: report of two cases.
    Sun TF; Lin PY; Wu CK
    Chang Gung Med J; 2001 Sep; 24(9):587-92. PubMed ID: 11725630
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Psychotherapeutic and pharmacological treatment of pediatric obsessive-compulsive disorder].
    Vloet TD; Simons M; Herpertz-Dahlmann B
    Z Kinder Jugendpsychiatr Psychother; 2012 Jan; 40(1):29-39; quiz 39-40. PubMed ID: 22161940
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Obsessive-compulsive disorder (OCD): Practical strategies for pharmacological and somatic treatment in adults.
    Fineberg NA; Reghunandanan S; Simpson HB; Phillips KA; Richter MA; Matthews K; Stein DJ; Sareen J; Brown A; Sookman D;
    Psychiatry Res; 2015 May; 227(1):114-25. PubMed ID: 25681005
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Obsessive-compulsive disorder.
    Bokor G; Anderson PD
    J Pharm Pract; 2014 Apr; 27(2):116-30. PubMed ID: 24576790
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder.
    McDougle CJ; Epperson CN; Pelton GH; Wasylink S; Price LH
    Arch Gen Psychiatry; 2000 Aug; 57(8):794-801. PubMed ID: 10920469
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The impact of obsessive beliefs on pharmacological treatment response in patients with obsessive-compulsive disorder.
    Selvi Y; Atli A; Besiroglu L; Aydin A; Gulec M
    Int J Psychiatry Clin Pract; 2011 Sep; 15(3):209-13. PubMed ID: 22121931
    [TBL] [Abstract][Full Text] [Related]  

  • 38. New developments in the treatment of obsessive-compulsive disorder.
    Leonard HL
    J Clin Psychiatry; 1997; 58 Suppl 14():39-45; discussion 46-7. PubMed ID: 9418745
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Refractory obsessive-compulsive disorder: state-of-the-art treatment.
    Hollander E; Bienstock CA; Koran LM; Pallanti S; Marazziti D; Rasmussen SA; Ravizza L; Benkelfat C; Saxena S; Greenberg BD; Sasson Y; Zohar J
    J Clin Psychiatry; 2002; 63 Suppl 6():20-9. PubMed ID: 12027116
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Calcium Signaling Pathway Is Associated with the Long-Term Clinical Response to Selective Serotonin Reuptake Inhibitors (SSRI) and SSRI with Antipsychotics in Patients with Obsessive-Compulsive Disorder.
    Umehara H; Numata S; Tajima A; Nishi A; Nakataki M; Imoto I; Sumitani S; Ohmori T
    PLoS One; 2016; 11(6):e0157232. PubMed ID: 27281126
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.